Use of aminoquinolines (Chloroquine and Hydroxychloroquine) in the treatment of COVID-19: a systematic review

• Autor(a) principal: Lima, Luan Victor Almeida
• Data de Publicação: 2021
• Outros Autores: Santos, Filipe Saboya, Alves, Nataly Abreu, Alves, Sabrina Sales, Melo, Iury Magalhães Dutra de, Bandeira, Tereza de Jesus Pinheiro Gomes
• Tipo de documento: Artigo
• Idioma: por
• Título da fonte: Research, Society and Development
• Texto Completo: https://rsdjournal.org/index.php/rsd/article/view/20907
• topic: COVID-19; SARS-COV-2; Cloroquina; Hidroxicloroquina.; Cloroquina; COVID-19; SARS-COV-2; Hidroxicloroquina.; COVID-19; SARS-COV-2; Chloroquine; Hydroxychloroquine.

The COVID-19 pandemic, caused by the SARS-COV-2 virus, is an infectious disease that to date there is no effective treatment to reduce patient mortality. Hydroxychloroquine (HCQ) and Chloroquine (CQ) are aminoquinoline-derived drugs used in the prevention and treatment of malaria. Initially, aminoquinolines were reported as effective in combating SARS-COV-2 due to their anti-inflammatory and antiviral effects, however, several studies were published in the literature, addressing their efficacy, leading to contradictory results. Furthermore, there is, to date, no concrete evidence to support their use, as well as, there is a small number of clinical trials that show evidence of the effectiveness of these drugs. Therefore, the present study aims to assess the effectiveness of HCQ and CQ in the treatment of patients with COVID-19, through a systematic review of the main articles involving patients with COVID-19 and the use of HCQ and CQ. A systematic review was performed based on a search in the PubMed and EMBASE databases to find articles that provide information on the efficacy and safety of formulations related to aminoquinolines in patients with SARS-CoV-2 pneumonia. The initial search identified a total of 162 articles, with 14 eligible, and 13 of these found no significant difference.